CD22 and Burkitt lymphoma: In human xenograft models of B ALL, of Burkitt’s lymphoma, of DLBCL, and of mantle cell lymphoma, responses to CD22-targeted immunotoxins were greatly enhanced by repeated or continuous administration via surgically implanted osmotic pumps [32,33].